Clinical trial · Observational
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
Yttrium-90 Selective Internal Radiation Therapy (SIRT) Combined With Lenvatinib and PD-(L)1 Inhibitors Versus Transarterial Chemoembolization (TACE) Combined With Lenvatinib and PD-(L)1 Inhibitors for Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitors (TACE-L-P) in patients with HCC beyond up-to-seven criteria or with portal vein tumor thrombus (PVTT). Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the two groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SIRT-L-P | Combination Product | — | UNRESOLVED |
| TACE-L-P | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- SIRT-L-P
- description
- Patients were treated with SIRT-L-P
- interventionNames
- Combination Product: SIRT-L-P
- label
- TACE-L-P
- description
- Patients were treated with TACE-L-P
- interventionNames
- Combination Product: TACE-L-P
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 32 months
- description
- The time from the first SIRT or TACE procedure until the date that progressive disease according to mRECIST or death was confirmed.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * histologically or clinically confirmed diagnosis of HCC at BCLC stage B or C (extrahepatic metastases were allowed) * Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 * Child-Pugh class A or B7 * unresectable HCC with intrahepatic tumor beyond up-to-seven criteria and/or with PVTT. Exclusion Criteria: * receipt of other loco-regional therapies, including hepatic arterial infusion chemotherapy, external radiation therapy, or radioactive seed implantation * Prior systemic therapy * History of other malignancies * incomplete medical records
References
Publications (0)
Data not yet available